Member Info for DJB67

Yes you can. But it’s consumer grade and classed as a Food Supplement. It hasn’t been tested against any medical criteria, and nor will it be because the companies who sell those products aren’t intending to make any medicinal claims.

Ananda are not in that game and that is why they are preparing rigorous trials with expert researchers and professors at respected universities and hospitals.

Another positive RNS announcement completion of Stability Trials for MRX1, which is a significant milestone and means the drug can now be used for dosing in patients.

@lolarose. Trials have started but are in pre-dosing prep stage. This entails the drafting of protocols, running risk assessments, dialogue with the MHRA, manufacturing MRX1 to GMP standards, submission of the trial to an ethics panel etc.

There is a blog about what happens before dosing starts in a clinical trials which can be found on the Ananda website.

OK, I suggest we both move on.

For the record though, I’ve always considered this high risk and I don’t think anyone, including Darren, think any different. That said, I think it is a bit more than a punt and with every positive announcement the company slightly reduce the risk of the proposition.

I’ll be honest and say I don’t know what the board are paid, but it ought to commensurate with the size of the business.

If you are going to research I suggest looking through the company website and specifically the Projects and Advisors sections. Also, join The Investor Hub and if you have questions then ask. I always get a response and usually within 24 business hours.

But, if you don’t trust the board of directors then I’m not sure how you get past that and if it were me I’d park Ananda and seek an investment where I had confidence in the board.

OK thanks, that’s interesting.

And again this is a genuine set of comments, not trying to wind you up, but I’d have thought given all the trials, tribulations and issues you encountered you’d have been more sympathetic to the Ananda cause particularly given you clearly believe in the benefits of CBD.

I get you were/are frustrated by the pace of Ananda, but in the context of what they are trying to do (make a big win with the NHS and in the US) this is inevitably going to take a lot longer than anything you were doing.

It sounds like you bought in at a point when the share price was up and ended up selling at a loss, which generally hurts. I feel that pain having lost a decent amount on Love Hemp.

I also understand your frustration with big pharma suppressing use of CBD to protect their products, and I think you have a genuine point with that.

But, GW Pharma proved it can be done and eventually big pharma in the shape of Jazz bought them out. That is the route Ananda wants to progress.

Yes, it’s high risk and yes it’s taking a long time but they have the govt on the hook for £11.5m and Ananda have some excellent advisors on board in the shape of respected professors and more recently the 2 ex GW Pharma execs. Both have down their due diligence before joining as advisors so to me they must think this has a chance.

Genuine questions….

If you are an expert, and I get you know about Cannabis, why are you not still growing? Why did you stop? And if you can do it, why don’t you startup again and show Ananda and everyone else how it is done?

I don’t need to check. I know for certain who posts under the username 60601971, and it isn’t Melissa. So continue with your dilusions because it doesn’t get you anywhere.

And if indeed Darren is using his birthday to make his username then you are entirely wrong as according to Companies House records Melissa was born in 1966!

So go find another board to troll you uninformed fool.

Are you threatening me! Haha! Silly boy go away!

Oh come font of all knowledge, I thought you knew where the company was spending money!

The majority of the dilution (over 2bn shares) went to Charles to repay the debt owed by the company for the £9m he has loaned the company over the last 6 years. The company already had approx 800m shares following their initial listing and the rest has been cash raises from other shareholders.

Cash has been used to acquire DJT Plants, build the trial growing facility, pay the expert growers, build the database of growing findings, pay advisors and staff involved in preparing for the trials such as as drafting of protocols, running risk assessments, dialogue with the MHRA, manufacturing MRX1 to GMP standards, submission of the trial to an ethics panel etc.

They’ve also funded the Phase 1 Pharmacokinetic trial for MRX1 and the pre clinical study of heart disease in Mice.

Are there you go again posting misinformation, once again proving you lack knowledge of how this company is operating.

Ananda are not funding the trials. How many times do I have to say that before you get into your head!

NHS Scotland has provided over £1.5m for the Phase 2 Endo and CIPN trials and NHS England has provided £10m for the Phase 3 Epilepsy trials.

And there you go again making defamatory statements that you have stated you cannot provide evidence to justify.

Ananda has reported the correct number of shares in issue. Read their RNS! Oh sorry, you don’t read the company info do you because you aren’t a shareholder.

Ananda cannot update the info on this board. It is the responsibility of LSE.

And here comes norfolk again adding nothing to this board.

LSE are responsible for updating this website not the company.

And yes, they’ve raised cash just like any developing company needs to do. But you don’t seem to be able to grasp that fact, which just goes to show how little you understand of business.

Haha! I’ve just realised where you got your £6.7m from. The overview page of this website! You can’t even go and find the correct info or do the maths for yourself! Well, sorry but the number of shares in issues stated in the overview page is woefully out of date. So how about you go back again and so some proper research and understand the company.

Incorrect. Based on a Mid price of 0.325 and 4.3bn shares is just under £14m. Do your maths again.

As J said, stop posting misinformation and I’ll stop.

As for tour comment on the share price…. No, the share price is representative of a company in development and currently without any revenue. Based on the number of shares in issue the current mcap is approx £14m, which isn’t bad for a company with no revenue and no significant physical assets.

Next!

That is twice you have confirmed you are not a shareholder and yesterday you confirmed you had no evidence for any of your statements about the company. So you come here to troll.

As for personal attacks, I will continue to challenge you if you continue to post misinformation about the company.

Quite simply, you stop and I’ll stop. But I’m quite enjoying myself to be honest, so you keep throwing them up and I’ll bat them back. It giving me an opportunity to show everyone what you are and also explain a bit more about the company.

Exactly this Darren. I’ve already managed to draw out of him that he is no longer a shareholder as he sold up some time ago. He has also confirmed he has no evidence to support any of his claims. He is just a troll.